| Business Summary | | Bausch
&
Lomb
Incorporated
is
engaged
in
the
development,
manufacture
and
marketing
of
healthcare
products
for
the
eye.
The
Company
has
three
business
segments,
vision
care,
pharmaceuticals
and
surgical.
The
vision
care
segment
includes
contact
lenses,
lens
care
products
and
vision
accessories.
The
pharmaceuticals
segment
includes
generic
and
proprietary
prescription
ophthalmic
drugs
and
over-the-counter
products,
with
an
emphasis
on
ophthalmic
medications.
The
surgical
segment
includes
cataract,
refractive
and
other
ophthalmic
surgery
products
and
equipment.
In
April
2001,
the
Company
announced
the
creation
of
a
new
company,
Technovision,
focused
on
the
research
and
development
of
new
refractive
surgical
technologies
for
vision
correction
and
enhancement. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Bausch
and
Lomb
Inc.
develops,
manufactures
and
markets
healthcare
products
for
the
eye
in
three
business
segments:
vision
care,
pharmaceuticals,
and
surgical.
For
the
six
months
ended
6/30/01,
revenues
fell
4%
to
$826.2
million.
Net
income
before
acct.
change
fell
93%
to
$5.5
million.
Revenues
reflect
a
decrease
in
lens
care,
pharmaceutical
and
refractive
sales.
Earnings
reflect
the
inclusion
of
a
$16.9
million
restructuring
charge. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| William Waltrip, 63 Chairman | -- | -- | Stephen McCluski, 48 CFO,
Sr. VP | $673K | $66K | Robert Stiles, 51 Sr.
VP and Gen. Counsel | -- | -- | Gary Aron, 58 Sr.
VP - Research, Devel., and Engineering | 324K | -- | Dwain Hahs, 48 Sr.
VP, Global Supply Chain Management | 645K | -- | Dollar
amounts are as of 30-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|